Resources from the same session
76MO - Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial
Presenter: Joon Oh Park
Session: Mini Oral session: Gastrointestinal tumours
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Presenter: Rashid Lui
Session: Mini Oral session: Gastrointestinal tumours
Resources:
Slides
Webcast